ADDUS HOMECARE CORP (ADUS)

US0067391062 - Common Stock

131.4  +1.8 (+1.39%)

After market: 131.4 0 (0%)

Fundamental Rating

7

Taking everything into account, ADUS scores 7 out of 10 in our fundamental rating. ADUS was compared to 109 industry peers in the Health Care Providers & Services industry. ADUS gets an excellent profitability rating and is at the same time showing great financial health properties. ADUS is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make ADUS suitable for growth and quality investing!



8

1. Profitability

1.1 Basic Checks

In the past year ADUS was profitable.
ADUS had a positive operating cash flow in the past year.
ADUS had positive earnings in each of the past 5 years.
In the past 5 years ADUS always reported a positive cash flow from operatings.

1.2 Ratios

The Return On Assets of ADUS (6.39%) is better than 88.89% of its industry peers.
Looking at the Return On Equity, with a value of 7.77%, ADUS is in the better half of the industry, outperforming 73.15% of the companies in the same industry.
ADUS has a Return On Invested Capital of 7.89%. This is in the better half of the industry: ADUS outperforms 76.85% of its industry peers.
ADUS had an Average Return On Invested Capital over the past 3 years of 7.41%. This is in line with the industry average of 8.15%.
The 3 year average ROIC (7.41%) for ADUS is below the current ROIC(7.89%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.39%
ROE 7.77%
ROIC 7.89%
ROA(3y)5.26%
ROA(5y)4.69%
ROE(3y)7.99%
ROE(5y)7.13%
ROIC(3y)7.41%
ROIC(5y)6.45%

1.3 Margins

With an excellent Profit Margin value of 6.50%, ADUS belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
In the last couple of years the Profit Margin of ADUS has grown nicely.
ADUS has a Operating Margin of 9.03%. This is amongst the best in the industry. ADUS outperforms 82.41% of its industry peers.
ADUS's Operating Margin has improved in the last couple of years.
ADUS has a Gross Margin (32.15%) which is comparable to the rest of the industry.
ADUS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9.03%
PM (TTM) 6.5%
GM 32.15%
OM growth 3Y9.99%
OM growth 5Y14.67%
PM growth 3Y10.91%
PM growth 5Y13.22%
GM growth 3Y3.16%
GM growth 5Y4.03%

8

2. Health

2.1 Basic Checks

ADUS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ADUS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADUS has been increased compared to 5 years ago.
ADUS has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 8.76 indicates that ADUS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.76, ADUS belongs to the top of the industry, outperforming 95.37% of the companies in the same industry.
ADUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.76
ROIC/WACC0.87
WACC9.05%

2.3 Liquidity

A Current Ratio of 2.11 indicates that ADUS has no problem at all paying its short term obligations.
ADUS has a better Current ratio (2.11) than 74.07% of its industry peers.
ADUS has a Quick Ratio of 2.11. This indicates that ADUS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ADUS (2.11) is better than 75.93% of its industry peers.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 2.11

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.47% over the past year.
ADUS shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.26% yearly.
Looking at the last year, ADUS shows a quite strong growth in Revenue. The Revenue has grown by 10.15% in the last year.
ADUS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.43% yearly.
EPS 1Y (TTM)20.47%
EPS 3Y13.56%
EPS 5Y18.26%
EPS Q2Q%13.04%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y11.45%
Revenue growth 5Y15.43%
Sales Q2Q%7.04%

3.2 Future

The Earnings Per Share is expected to grow by 13.91% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.94% on average over the next years. This is quite good.
EPS Next Y17.81%
EPS Next 2Y14.8%
EPS Next 3Y13.91%
EPS Next 5YN/A
Revenue Next Year7.42%
Revenue Next 2Y11.66%
Revenue Next 3Y11.94%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 25.37, the valuation of ADUS can be described as expensive.
64.81% of the companies in the same industry are more expensive than ADUS, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.73. ADUS is around the same levels.
ADUS is valuated rather expensively with a Price/Forward Earnings ratio of 22.11.
ADUS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ADUS is cheaper than 61.11% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. ADUS is around the same levels.
Industry RankSector Rank
PE 25.37
Fwd PE 22.11

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ADUS.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ADUS indicates a somewhat cheap valuation: ADUS is cheaper than 76.85% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 18.85
EV/EBITDA 18.28

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADUS has an outstanding profitability rating, which may justify a higher PE ratio.
ADUS's earnings are expected to grow with 13.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.42
PEG (5Y)1.39
EPS Next 2Y14.8%
EPS Next 3Y13.91%

0

5. Dividend

5.1 Amount

No dividends for ADUS!.
Industry RankSector Rank
Dividend Yield N/A

ADDUS HOMECARE CORP

NASDAQ:ADUS (12/20/2024, 8:00:00 PM)

After market: 131.4 0 (0%)

131.4

+1.8 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)N/A N/A
Inst Owners95.33%
Inst Owner Change-5.05%
Ins Owners26.29%
Ins Owner Change0.69%
Market Cap2.38B
Analysts84.71
Price Target141.37 (7.59%)
Short Float %2.39%
Short Ratio3.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.16%
Min EPS beat(2)-0.68%
Max EPS beat(2)9%
EPS beat(4)3
Avg EPS beat(4)6.88%
Min EPS beat(4)-0.68%
Max EPS beat(4)10.37%
EPS beat(8)7
Avg EPS beat(8)7.29%
EPS beat(12)10
Avg EPS beat(12)5.22%
EPS beat(16)11
Avg EPS beat(16)4.27%
Revenue beat(2)0
Avg Revenue beat(2)-1.57%
Min Revenue beat(2)-1.83%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-1.83%
Max Revenue beat(4)-1.28%
Revenue beat(8)0
Avg Revenue beat(8)-1.26%
Revenue beat(12)0
Avg Revenue beat(12)-1.69%
Revenue beat(16)0
Avg Revenue beat(16)-2.15%
PT rev (1m)0.95%
PT rev (3m)3.86%
EPS NQ rev (1m)-0.96%
EPS NQ rev (3m)-2.33%
EPS NY rev (1m)-0.29%
EPS NY rev (3m)-0.3%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-1.78%
Valuation
Industry RankSector Rank
PE 25.37
Fwd PE 22.11
P/S 2.1
P/FCF 18.85
P/OCF 17.51
P/B 2.51
P/tB 12.07
EV/EBITDA 18.28
EPS(TTM)5.18
EY3.94%
EPS(NY)5.94
Fwd EY4.52%
FCF(TTM)6.97
FCFY5.31%
OCF(TTM)7.5
OCFY5.71%
SpS62.54
BVpS52.27
TBVpS10.89
PEG (NY)1.42
PEG (5Y)1.39
Profitability
Industry RankSector Rank
ROA 6.39%
ROE 7.77%
ROCE 10.29%
ROIC 7.89%
ROICexc 10.16%
ROICexgc 356.56%
OM 9.03%
PM (TTM) 6.5%
GM 32.15%
FCFM 11.15%
ROA(3y)5.26%
ROA(5y)4.69%
ROE(3y)7.99%
ROE(5y)7.13%
ROIC(3y)7.41%
ROIC(5y)6.45%
ROICexc(3y)8.47%
ROICexc(5y)7.58%
ROICexgc(3y)87.71%
ROICexgc(5y)69.95%
ROCE(3y)9.67%
ROCE(5y)8.41%
ROICexcg growth 3Y24.91%
ROICexcg growth 5Y31.22%
ROICexc growth 3Y10.93%
ROICexc growth 5Y1.53%
OM growth 3Y9.99%
OM growth 5Y14.67%
PM growth 3Y10.91%
PM growth 5Y13.22%
GM growth 3Y3.16%
GM growth 5Y4.03%
F-Score7
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 69.13%
Cap/Sales 0.85%
Interest Coverage 13.31
Cash Conversion 116.95%
Profit Quality 171.61%
Current Ratio 2.11
Quick Ratio 2.11
Altman-Z 8.76
F-Score7
WACC9.05%
ROIC/WACC0.87
Cap/Depr(3y)52.67%
Cap/Depr(5y)51.52%
Cap/Sales(3y)0.77%
Cap/Sales(5y)0.78%
Profit Quality(3y)150.66%
Profit Quality(5y)158.26%
High Growth Momentum
Growth
EPS 1Y (TTM)20.47%
EPS 3Y13.56%
EPS 5Y18.26%
EPS Q2Q%13.04%
EPS Next Y17.81%
EPS Next 2Y14.8%
EPS Next 3Y13.91%
EPS Next 5YN/A
Revenue 1Y (TTM)10.15%
Revenue growth 3Y11.45%
Revenue growth 5Y15.43%
Sales Q2Q%7.04%
Revenue Next Year7.42%
Revenue Next 2Y11.66%
Revenue Next 3Y11.94%
Revenue Next 5YN/A
EBIT growth 1Y17.51%
EBIT growth 3Y22.58%
EBIT growth 5Y32.37%
EBIT Next Year37.95%
EBIT Next 3Y22.85%
EBIT Next 5YN/A
FCF growth 1Y24.25%
FCF growth 3Y0.06%
FCF growth 5Y29.8%
OCF growth 1Y28.34%
OCF growth 3Y0.86%
OCF growth 5Y27.59%